ASCO GU 2018: Ten-year final results of the TROG 03.04 (RADAR) randomised phase-III trial

Historical data from RTOG 92.02 and EORTC 22961 have shown that long-term androgen deprivation therapy (ADT) is more effective than short-term ADT in men undergoing radiotherapy for clinically localised intermediate or high risk prostate cancer. However, long-term ADT carries with it a range of side-effects including sexual dysfunction, weight gain, bone density loss, cognitive dysfunction, and sarcopenia, to name a few.
Uro Today

Leave a Reply

  • (will not be published)

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>